Mucolytics for bronchiectasis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Wilkinson, Mark ^a   Sugumar, Karnam ^b   Milan, Stephen J ^c   Hart, Anna ^d   Crockett, Alan ^e   Crossingham, Iain ^f  

^a UNIVERSITY HOSPITALS OF MORECAMBE BAY NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL PRESTON HOSPITAL   (United Kingdom)

^c LANCASTER UNIVERSITY   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^f ROYAL BLACKBURN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BROMHEXINE; DEOXYRIBONUCLEASE; ERDOSTEINE; PLACEBO; ANTIINFECTIVE AGENT; EXPECTORANT AGENT; RECOMBINANT PROTEIN; THIOGLYCOLIC ACID DERIVATIVE; THIOPHENE DERIVATIVE;

BRONCHIECTASIS; DISEASE DURATION; DISEASE EXACERBATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITALIZATION; HUMAN; INFLUENZA; MORTALITY RATE; MUCUS SECRETION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPIROMETRY; SPUTUM ANALYSIS; SYSTEMATIC REVIEW; DRUG COMBINATION; META ANALYSIS;

ANTI-BACTERIAL AGENTS; BROMHEXINE; BRONCHIECTASIS; DEOXYRIBONUCLEASES; DRUG THERAPY, COMBINATION; EXPECTORANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; THIOGLYCOLATES; THIOPHENES;

EID: 84921447163     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001289.pub2     Document Type: Review

References (50)

1. Crisafulli E, Coletti O, Costi S, Zanasi E, Lorenzi C, Lucic S, et al. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clinical Therapeutics 2007;29(9):2001-9.
2. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113(5):1329-34. [CRS-ID: 4900100000006002]
3. Olivieri D, Ciaccia A, Marangio E, Marsico S, Todisco T, Del Vita M. Role of bromhexine in exacerbations of bronchiectasis. Double-blind randomized multicenter study versus placebo. Respiration 1991;58(3-4):117-21. [CRS-ID: 4900100000003559;: 4900100000003559]
4. Wills PJ, Wodehouse T, Corkery K, Mallon K, Wilson R, Cole PJ. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability. American Journal of Respiratory and Critical Care Medicine 1996;154(2 Pt 1):413-7. [CRS-ID: 4900100000005313;: 4900100000005313]
5. Alberto S, Colongo PG, Brusasco L, Frigerio G. [Studies of the clinical and respiratory functional effects of a mucolytic-antibiotic preparation in chronic bronchopulmonary diseases. Controlled double-blind single code studies] [Studi sugli effetti clinici e sulla funzionalità respiratoria di un preparato mucolitico-antibiotico nelle affezioni croniche broncopolmonari. Ricerca controllata doppio-cieca a codifica singola]. Minerva Medica 1968;59(53):2995-3002. [CRS-ID: 4900100000000090]
6. Balzano E, De Gaetani G. [D1-sobrerol in the treatment of acute and chronic bronchopulmonary phlogoses]. [Italian] [Il dl sobrerolo nel trattamento delle flogosi broncopolmonari acute e croniche]. Minerva Medica 1973;64(37):1995-2002. [CRS-ID: 4900100000055881]
7. Bateman PP. A new mucolytic, bromhexine ('bisolvon'). A double-blind study. Medical Journal of Australia 1971;1(18):963-5. [CRS-ID: 4900100000009066]
8. Benjamin C. The use and efficacy of mucolytic agents. South African Medical Journal 1971; Vol. 45, issue 34:948-52. [CRS-ID: 4900100000000295]
9. Bergogne Berezin E, Berthelot G, Kafe HP, Dournovo P. Influence of a fluidifying agent (bromhexine) on the penetration of antibiotics into respiratory secretions. International Journal of Clinical Pharmacology Research 1985;5(5):341-4. [CRS-ID: 4900100000001832]
10. Bradley JM, Treacy K, O'Neill B, McCourt F, Green L, Gardner E, et al. A randomised double blind 13 week crossover trial of hypertonic saline (HTS) (6%) vs isotonic saline (ITS) (0.9%) in patients with bronchiectasis [Abstract]. Thorax 2011;66(Suppl 4):A49 [S106]. [CRS-ID: 4900100000054250]
11. Cobbin DM, Elliott FM, Rebuck AS. The mucolytic agent bromhexine (Bisolvon) in chronic lung disease: a double-blind crossover trial. Australian and New Zealand Journal of Medicine 1971;2:137-40.
12. Currie DC, Greenstone M, Pavia D, Agnew JE, Pellow P, Clarke SW, et al. Efficacy of 'mucoregulatory' agents in Young's syndrome. Thorax 1988;43(6):480-1. [CRS-ID: 4900100000007454]
13. Daviskas E, Anderson SD, Eberl S, Chan HK, Bautovich G, Anderson S, et al. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. American Journal of Respiratory and Critical Care Medicine 1999;159(6):1843-8. [CRS-ID: 4900100000008890;: 4900100000008890]
14. Fadda G. Oral neltenexine in patients with obstructive airways diseases: an open, randomised, controlled comparison versus sobrerol. Minerva Medica 2001;92(4):269-75. [CRS-ID: 4900100000011117;: 4900100000011117]
15. Germouty J, Jirou-Najou JL. Clinical trial of ambroxol in 2 different dosage programs in 120 patients with bronchiectasis. [Portuguese]. Revista Brasileira de Clinica E Terapeutica 1988;17(1-2):33-6. [CRS-ID: 4900100000050034]
16. Ghiringhelli G. Feprazone plus bromhexine in treatment of flare-ups of chronic bronchopathies. [Italian]. Archivio Di Medicina Interna 1981;33(2):157-68. [CRS-ID: 4900100000050043]
17. Hasani A, Pavia D, Spiteri MA, Yeo CT, Agnew JE, Clarke SW, et al. Regional mucus transport following unproductive cough and forced expiration technique in patients with airways obstruction. European Respiratory Journal 1994;105(5):1420-5. [CRS-ID: 4900100000004379]
18. Hasani A, Pavia D, Agnew JE, Clarke SW. Regional lung clearance during cough and forced expiration technique (FET): effects of flow and viscoelasticity. Thorax 1994;49(6):557-61. [CRS-ID: 4900100000004427]
19. Itoh K, Kounou O, Morise M, Iwakura M, Misutani N, Katayama T, et al. Clinical effects of proteinase, sfericase (AI-794), on chronic bronchitis and similar diseases. International Journal of Clinical Pharmacology, Therapy, and Toxicology 1984;22(1):32-8. [CRS-ID: 4900100000001525]
20. Kawashima K, Yamamoto H, Kadoya M, Kato M, Nata T, Iida E, et al. Clinical role of Branhamella catarrhalis infection in pulmonary disorders. [Japanese]. Saishin Igaku [Modern Medicine] 1989;44(6):1268-72. [CRS-ID: 4900100000050022]
21. Kellett F, Redfern J, Niven RM, Kellet F. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respiratory Medicine 2005;99(1):27-31. [CRS-ID: 4900100000017992]
22. Kossmagk R. Ultrasonic aerosol apparatus hire system - Therapy of chronic obstructive bronchitis and bronchiectasia. [German]. Zeitschrift Fur Erkrankungen der Atmungsorgane 1980;155(1):125-7. [CRS-ID: 4900100000050047]
23. Loukides S, Kharitonov S, Wodehouse T, Cole PJ, Barnes PJ. Effect of arginine on mucociliary function in primary ciliary dyskinesia. Lancet 1998;352(9125):371-2. [CRS-ID: 4900100000023280;: 4900100000023280]
24. Mareels J. A long term tolerance trial of bromhexine. Acta Therapeutica 1983;9(3):305-15. [CRS-ID: 4900100000055851]
25. Marthin JK, Mortensen J, Pressler T, Nielsen KG. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest 2007;132(3):966-76. [CRS-ID: 4900100000021265;: 4900100000021265]
26. Noone PG, Bennett WD, Regnis JA, Zeman KL, Carson JL, King M, et al. Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. American Journal of Respiratory and Critical Care Medicine 1999;160(1):144-9. [CRS-ID: 4900100000006450;: 4900100000006450]
27. Patterson JE, Hewitt O, Kent L, Bradbury I, Elborn JS, Bradley JM. Acapella versus 'usual airway clearance' during acute exacerbation in bronchiectasis: a randomized crossover trial. Chronic Respiratory Disease 2007;4(2):67-74. [CRS-ID: 4900100000024010]
28. Sahay JN, Chatterjee SS, Ingram DF. The effect of methyl cysteine (Visclair) in respiratory diseases. A pilot study. Clinical Trials Journal 1982;19(3):137-43. [CRS-ID: 4900100000006790]
29. Serisier DJ, Martin ML, McGuckin MA, Lourie R, Chen AC, Brain B, et al. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. JAMA 2013; Vol. 309, issue 12:1260-7.
30. Stafanger G, Garne S, Howitz P, Morkassel E, Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. The European Respiratory Journal 1988;1(2):161-7. [CRS-ID: 4900100000002512;: 4900100000002512]
31. Tambascio J, de Souza LT, Lisboa RM, Passarelli RDCV, de Souza HCD, Gastaldi AC. The influence of Flutter VRP1 components of mucus transport of patients with bronchiectasis. Respiratory Medicine 2011;105(9):1316-21. [CRS-ID: 4900100000050220]
32. Taskar VS, Sharma RR, Goswami R, John PJ, Mahashur AA. Effect of bromhexine on sputum amoxycillin levels in lower respiratory infections. Respiratory Medicine 1992;86(2):157-60. [CRS-ID: 4900100000003765;: 4900100000003765]
33. Tsang SMH, Jones AYM, Tsang SM H, Jones AYM. Postural drainage or flutter device in conjunction with breathing and coughing compared to breathing and coughing alone in improving secretion removal and lung function in patients with acute exacerbation of bronchiectasis. A pilot study. Hong Kong Physiotherapy Journal 2003;21:29-36. [CRS-ID: 4900100000016230]
34. Verstraeten JM. Mucolytic treatment in chronic obstructive lung disease: double-blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo. Acta Tuberculosea et Pneumologica Belgica 1979;70(1):71-80.
35. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, et al. Azithromycin for prevention of exacerbations in non-cystic. Lancet 2012;380(9842):660-7. [CRS-ID: 4900100000063431]
36. Yalçin E, Kiper N, Ozçelik U, Doğru D, Firat P, Sahin A, et al. Effects of clarithromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. Journal of Clinical Pharmacy and Therapeutics 2006;31(1):49-55. [CRS-ID: 4900100000019496]
37. Balsamo R, Lanata L, Egan CG. Mucoactive drugs. European Respiratory Review 2010;19(116):127-33.
38. Pasteur MC, Bilton D, Hill AT. BTS guideline for non-CF bronchiectasis. www.brit-thoracic.org.uk/LinkClick.aspx?link=496&tabid=69 (accessed 15 November 2013).
39. Cotgreave I, Eklund A, Larsson K, Moldéus P. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. European Journal of Respiratory Diseases 1987;70(2):73-7.
40. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgraduate Medical Journal 2010;86:493-501.
41. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatric Respiratory Reviews 2007;8(1):24-9.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
43. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
44. Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. Respiratory Care 2007;52(9):1176-97.
45. Stafler P, Carr S. Non cystic fibrosis bronchiectasis: its diagnosis and management. Archives of Diseases in Childhood. Education and Practice Edition 2010;95:73-82.
46. Stockley RA. Role of inflammation in respiratory tract infections. American Journal of Medicine 1995;99(6):8S-13S.
47. Tomkiewicz RP, App EM, De Sanctis GT, Coffiner M, Maes P, Rubin BK, et al. A comparison of a new mucolytic N-acetylcysteine l-lysinate with N-acetylcysteine: airway epithelial function and mucus changes in dog. Pulmonary Pharmacology 1995;8(6):259-65.
48. TSANZ and the Lung Foundation. Chronic suppurative lung disease and bronchiectasis in children and adults 2010. http://www.lungfoundation.com.au/professional-resources/guidelines/(accessed 15 November 2013).
49. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cellular and Molecular Life Sciences 2003;60(1):6-20.
50. Crockett A, Cranston JM, Alpers JH, Latimer KM. Mucolytics for bronchiectasis. Cochrane Database of Systematic Reviews 2001, Issue 1. [DOI: 10.1002/14651858.CD001289]